The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://ronaldtzko834079.blogars.com/37676316/glp-3-retatrutide-a-comparative-analysis